| Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases KM Wagner, CB McReynolds, WK Schmidt, BD Hammock Pharmacology & therapeutics 180, 62-76, 2017 | 240 | 2017 |
| Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative BD Hammock, CB McReynolds, K Wagner, A Buckpitt, I Cortes-Puch, ... Journal of medicinal chemistry 64 (4), 1856-1872, 2021 | 91 | 2021 |
| Epoxy fatty acids are promising targets for treatment of pain, cardiovascular disease and other indications characterized by mitochondrial dysfunction, endoplasmic stress and … C McReynolds, C Morisseau, K Wagner, B Hammock Druggable lipid signaling pathways, 71-99, 2020 | 53 | 2020 |
| Plasma linoleate diols are potential biomarkers for severe COVID-19 infections CB McReynolds, I Cortes-Puch, R Ravindran, IH Khan, BG Hammock, ... Frontiers in Physiology 12, 663869, 2021 | 47 | 2021 |
| Pharmaceutical effects of inhibiting the soluble epoxide hydrolase in canine osteoarthritis CB McReynolds, SH Hwang, J Yang, D Wan, K Wagner, C Morisseau, ... Frontiers in pharmacology 10, 533, 2019 | 34 | 2019 |
| Development of improved double-nanobody sandwich ELISAs for human soluble epoxide hydrolase detection in peripheral blood mononuclear cells of diabetic patients and the … D Li, C Morisseau, CB McReynolds, T Duflot, J Bellien, RM Nagra, ... Analytical chemistry 92 (10), 7334-7342, 2020 | 32 | 2020 |
| sEH-derived metabolites of linoleic acid drive pathologic inflammation while impairing key innate immune cell function in burn injury CB Bergmann, CB McReynolds, D Wan, N Singh, H Goetzman, ... Proceedings of the National Academy of Sciences 119 (13), e2120691119, 2022 | 30 | 2022 |
| In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea D Wan, J Yang, CB McReynolds, B Barnych, KM Wagner, C Morisseau, ... Frontiers in pharmacology 10, 464, 2019 | 27 | 2019 |
| Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses R Ravindran, C McReynolds, J Yang, BD Hammock, A Ikram, A Ali, ... PloS one 16 (7), e0254367, 2021 | 22 | 2021 |
| Soluble epoxide hydrolase regulation of lipid mediators limits pain KM Wagner, A Gomes, CB McReynolds, BD Hammock Neurotherapeutics 17 (3), 900-916, 2020 | 21 | 2020 |
| Clinical and preclinical evidence for roles of soluble epoxide hydrolase in osteoarthritis knee pain PRW Gowler, J Turnbull, M Shahtaheri, S Gohir, T Kelly, C McReynolds, ... Arthritis & Rheumatology 74 (4), 623-633, 2022 | 11 | 2022 |
| Lipidomes of brain from rats acutely intoxicated with diisopropylfluorophosphate identifies potential therapeutic targets J Yang, DA Bruun, C Wang, D Wan, CB McReynolds, K Phu, B Inceoglu, ... Toxicology and applied pharmacology 382, 114749, 2019 | 11 | 2019 |
| Advancing soluble epoxide hydrolase inhibitors through the valley of death into phase 1 clinical trials for treating painful diabetic neuropathy by utilizing university … C McReynolds, WK Schmidt, K Wagner, BD Hammock The FASEB Journal 30, 1272.6-1272.6, 2016 | 10 | 2016 |
| Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression C McReynolds, B Hammock, C Morisseau Pharmacology & Therapeutics, 108454, 2023 | 6 | 2023 |
| The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling A Luo, Z Wu, S Li, CB McReynolds, D Wang, H Liu, C Huang, T He, ... Journal of translational medicine 21 (1), 71, 2023 | 6 | 2023 |
| Improved ELISA for linoleate-derived diols in human plasma utilizing a polyHRP-based secondary tracer N Singh, D Li, CB McReynolds, C Morisseau, BD Hammock Analytical Methods 14 (18), 1810-1819, 2022 | 2 | 2022 |
| Species differences in metabolism of soluble epoxide hydrolase inhibitor, EC1728, highlight the importance of clinically relevant screening mechanisms in drug development CB McReynolds, J Yang, A Guedes, C Morisseau, R Garcia, H Knych, ... Molecules 26 (16), 5034, 2021 | 2 | 2021 |
| Pharmacokinetics of a potent soluble epoxide hydrolase inhibitor in three formulations J Yang, K Wagner, D Wan, SH Hwang, CB McReynolds, BD Hammock The FASEB Journal 34 (S1), 1-1, 2020 | 1 | 2020 |
| Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as an non-addictive opioid alternative K Lee, SH Hwang, C McReynolds, K Wagner, B Inceoglu, C Morisseau, ... Abstracts of Papers of the American Chemical Society 258, 2019 | 1 | 2019 |
| Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines R Ravindran, H Kang, C McReynolds, GK Sanghar, WLW Chang, ... Plos one 18 (10), e0287377, 2023 | | 2023 |
